Recent News for ATNM - Actinium Pharmaceuticals, Inc.

Date Title
Dec 11 Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Dec 11 Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Dec 8 Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
Nov 6 Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
Nov 3 Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
Nov 2 Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
Nov 2 Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
Oct 31 Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Oct 4 Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
Sep 27 Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
Back to the Main ATNM Page...